TD Cowen Lowers Enovix (NASDAQ:ENVX) Price Target to $7.50

Enovix (NASDAQ:ENVX) had its price target dropped by investment analysts at TD Cowen from $15.00 to $7.50 in a research report issued on Thursday, Marketbeat.com reports. The firm presently has a “hold” rating on the stock. TD Cowen’s price objective points to a potential upside of 42.31% from the stock’s previous close.

ENVX has been the topic of several other reports. JPMorgan Chase & Co. decreased their price objective on Enovix from $12.00 to $10.00 and set a “neutral” rating on the stock in a report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Enovix in a research report on Monday, December 29th. Oppenheimer set a $24.00 price objective on shares of Enovix in a research report on Thursday, November 6th. Canaccord Genuity Group reduced their target price on shares of Enovix from $22.00 to $21.00 and set a “buy” rating on the stock in a report on Thursday, November 6th. Finally, Northland Securities set a $16.00 price target on shares of Enovix in a report on Monday, November 17th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.65.

Enovix Stock Down 11.4%

ENVX opened at $5.27 on Thursday. The firm has a 50-day simple moving average of $7.10 and a two-hundred day simple moving average of $8.90. Enovix has a 52 week low of $5.24 and a 52 week high of $16.49. The company has a market capitalization of $1.14 billion, a PE ratio of -6.84 and a beta of 2.13. The company has a quick ratio of 9.47, a current ratio of 9.72 and a debt-to-equity ratio of 1.74.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Enovix by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 98,318 shares of the company’s stock worth $722,000 after acquiring an additional 4,780 shares in the last quarter. NewEdge Advisors LLC grew its stake in Enovix by 10.4% in the first quarter. NewEdge Advisors LLC now owns 26,257 shares of the company’s stock valued at $193,000 after purchasing an additional 2,481 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Enovix by 65.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,137,777 shares of the company’s stock worth $8,351,000 after purchasing an additional 449,934 shares in the last quarter. Caxton Associates LLP purchased a new stake in shares of Enovix during the first quarter valued at about $190,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Enovix by 18.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 358,023 shares of the company’s stock valued at $2,628,000 after buying an additional 55,676 shares in the last quarter. 50.92% of the stock is currently owned by institutional investors.

Enovix News Summary

Here are the key news stories impacting Enovix this week:

• Positive Sentiment: Q4 results beat expectations: revenue of ~$11.3M (+~16% YoY) topped estimates and EPS/loss was slightly better than forecast; gross profit and operating-loss improvement were highlighted on the call — a fundamental bright spot supporting longer‑term growth potential. SA Q4 Presentation
• Positive Sentiment: Multiple outlets noted the revenue and EPS beats and operational improvement (higher gross profit, narrower operating loss), which help the growth narrative even as profitability remains distant. Yahoo Finance: Q4 Report
• Neutral Sentiment: Unusual options activity: a large block of call buying (≈31,896 calls) indicates speculative/leveraged interest that may amplify intraday moves but doesn’t change fundamentals. AAII Options Note
• Neutral Sentiment: Some analysts lowered price targets but kept constructive ratings (e.g., Canaccord trimmed its PT but remains “Buy”), which mutes upside while signaling continued long‑term conviction from parts of the sell‑side. Benzinga: Canaccord Note
• Negative Sentiment: Near‑term guidance disappointed: Q1 FY2026 revenue guidance ($6.5M–$7.5M) came in well below consensus (~$8.8M), a key proximate reason for selling pressure as it implies slower near‑term growth. Company Press Release / Deck
• Negative Sentiment: Analyst downgrades/target cuts: TD Cowen cut its target sharply and moved to “Hold,” and other firms trimmed targets — increasing near‑term downside risk as sell‑side expectations are reset. Benzinga: TD Cowen Note
• Negative Sentiment: New risk disclosure highlights rising geopolitical/trade exposure (U.S.–China tensions) that could pressure supply chains and margins — a fresh governance/operational risk investors must price in. TipRanks: Risk Disclosure
• Negative Sentiment: Balance‑sheet and liquidity signals are concerning to some investors: cash fell year‑over‑year and total liabilities rose materially; coupled with insider sales called out in reporting, that has likely amplified selling. Quiver Quant: Financials

Enovix Company Profile

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.